Person:
Davis, Robert L.

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Davis

First Name

Robert L.

Name

Davis, Robert L.
Author's Publications: search.filters.isAuthorOfPublication.16dfbe6e-30bb-4a09-b13d-98c3e0e823ea

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    The Force of Union: Affect and Ascent in the Theology of Bonaventure
    (2012-08-08) Davis, Robert L.; Hollywood, Amy Maria
    The image of love as a burning flame is so widespread in the history of Christian literature as to appear inevitable. But as this dissertation explores, the association of amor with fire played a precise and wide-ranging role in Bonaventure's understanding of the soul's motive power--its capacity to love and be united with God, especially as that capacity was demonstrated in an exemplary way through the spiritual ascent and death of St. Francis. In drawing out this association, Bonaventure develops a theory of the soul and its capacity for transformation in union with God that gives specificity to the Christian desire for self-abandonment in God and the annihilation of the soul in union with God. Though Bonaventure does not use the language of the soul coming to nothing, he describes a state of ecstasy or excessus mentis that is possible in this life, but which constitutes the death and transformation of the soul in union with God. In this ecstatic state, the boundaries between the soul and God--between active and passive, mover and moved, will and necessity--are effectively consumed in the fire of union. This dissertation offers a new approach to the role of affect in Bonaventure’s theology through three lenses: his elaboration of the soul’s union with God as inspired by the writings of Dionysius the Areopagite; Bonaventure’s conception of synderesis or the soul’s natural affective “weight” or inclination to God; and the ecstatic death of the soul that Bonaventure describes in the Itinerarium mentis in Deum and which is witnessed in the body of St. Francis in the Legenda Maior. This dissertation argues that Bonaventure’s “affective" gloss on the Dionysian corpus was not an interpolation but a working out of the Dionysian conception of eros. In elaborating the soul’s natural motion to the good, moreover, Bonaventure situates divine desire within an Aristotelian cosmos. And as the manifestation of this desire in Francis’s dying body makes evident, for Bonaventure affectus plays at the boundary of body and spirit and names a force that is more fundamental than the distinction between the corporeal and incorporeal.
  • Thumbnail Image
    Publication
    Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study
    (Oxford University Press, 2012) Bowles, Erin J. Aiello; Wellman, Robert; Feigelson, Heather Spencer; Onitilo, Adedayo A.; Freedman, Andrew N.; Delate, Thomas; Allen, Larry A.; Nekhlyudov, Larissa; Goddard, Katrina A. B.; Davis, Robert L.; Habel, Laurel A.; Yood, Marianne Ulcickas; Mccarty, Catherine; Magid, David J.; Wagner, Edward
    Background: Clinical trials demonstrated that women treated for breast cancer with anthracycline or trastuzumab are at increased risk for heart failure and/or cardiomyopathy (HF/CM), but the generalizability of these findings is unknown. We estimated real-world adjuvant anthracycline and trastuzumab use and their associations with incident HF/CM. Methods We conducted a population-based, retrospective cohort study of 12 500 women diagnosed with incident, invasive breast cancer from January 1, 1999 through December 31, 2007, at eight integrated Cancer Research Network health systems. Using administrative procedure and pharmacy codes, we identified anthracycline, trastuzumab, and other chemotherapy use. We identified incident HF/CM following chemotherapy initiation and assessed risk of HF/CM with time-varying chemotherapy exposures vs no chemotherapy. Multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) with adjustment for age at diagnosis, stage, Cancer Research Network site, year of diagnosis, radiation therapy, and comorbidities. Results: Among 12 500 women (mean age = 60 years, range = 22–99 years), 29.6% received anthracycline alone, 0.9% received trastuzumab alone, 3.5% received anthracycline plus trastuzumab, 19.5% received other chemotherapy, and 46.5% received no chemotherapy. Anthracycline and trastuzumab recipients were younger, with fewer comorbidities than recipients of other chemotherapy or none. Compared with no chemotherapy, the risk of HF/CM was higher in patients treated with anthracycline alone (adjusted HR = 1.40, 95% CI = 1.11 to 1.76), although the increased risk was similar to other chemotherapy (adjusted HR = 1.49, 95% CI = 1.25 to 1.77); the risk was highly increased in patients treated with trastuzumab alone (adjusted HR = 4.12, 95% CI = 2.30 to 7.42) or anthracycline plus trastuzumab (adjusted HR = 7.19, 95% CI = 5.00 to 10.35). Conclusions: Anthracycline and trastuzumab were primarily used in younger, healthier women and associated with increased HF/CM risk compared with no chemotherapy. This population-based observational study complements findings from clinical trials on cancer treatment safety.